Study: GAL-001: Adaptive Phase II in Refractory Melanoma
Phase II
· Site: St. Brigid University Hospital (Dr. C. Nolan)
· consented 2026-07-08
Adverse events
2
Serious AEs
1
Open data queries
1
Luna dropout signal
+0.1
Adverse events
severe
serious
under_review
2026-08-18
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-11-11 (study day 469); relationship: not assessed; serious criteria: hospitalization
mild
assessed
2026-08-18
Participant-reported via Luna chat: "I've had some nausea since yesterday evening". Solicited symptom report logged for the next visit review.
Data queries
conmed_dose
needs_human
Reported dose conflicts with pharmacy dispensing log; clinical interpretation needed (cross-check against deviation pattern "Subject received another investigational drug concurrently").
☾ Luna engagement
Messages
4
Escalations
0
Check-ins
1
Mood ø
3.0
Med adherence · 7d
43%
Last check-in
2026-08-18
📅 Next appointment: Symptom review call
on 2026-08-19